Physician profile
Thomas C Beller
NPI 1568446581
$3,164.04
in general payments reported to CMS, 2019-2025
20 companies · $606 in 2025
The $606 reported for 2025 was less than what a typical Clinical & Laboratory Immunology (Allergy & Immunology) provider received nationally (typical 2025 total: $1,390).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $320 · 2021: $664 · 2022: $521 · 2023: $420 · 2024: $448 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.65 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,340.72 | 2021-2025 | Haegarda, Andembry, Hizentra |
| Astrazeneca Pharmaceuticals LP | $417.74 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Kaleo, INC. | $209.24 | 2019-2022 | |
| Glaxosmithkline, LLC. | $207.42 | 2019-2025 | Nucala |
| Optinose US, INC. | $128.72 | 2020-2023 | |
| Biocryst US Sales Co., LLC | $115.83 | 2021-2023 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $97.66 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $97.25 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $81.86 | 2022-2025 | |
| Pharming Healthcare, INC. | $80.63 | 2021-2025 | Ruconest |
| Amgen INC. | $73.11 | 2022-2024 | Tezspire |
| Grifols USA, LLC | $57.40 | 2021-2023 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $49.10 | 2022-2025 | Eohilia |
| Genzyme Corporation | $40.29 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $36.01 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $34.54 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $33.09 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $27.57 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $18.33 | 2025 | Dawnzera |
| Hikma Pharmaceuticals USA | $17.53 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Beller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.